Abstract
121 patients with active rheumatoid arthritis, 91 of whom had proved intolerant of other nonsteroidal anti-inflammatory agents, were treated for a mean of 10 months with naproxen. A dosage of 250 mg twice daily produced sustained improvement in most of the standard clinical measurements. 28 patients complained of side effects, with a lower than expected incidence of gastrointestinal complaints and no drug-induced rash being recorded. 19 patients withdrew from the trial because of side effects, while a further 22 withdrew because the drug was ineffective. Naproxen is a useful drug for long-term use in patients with rheumatoid arthritis, including those who have proved intolerant of or experienced inadequate symptomatic relief from other nonsteriodal anti-inflammatory agents.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boardman P. L., Hart F. D. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. Br Med J. 1967 Nov 4;4(5574):264–268. doi: 10.1136/bmj.4.5574.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huskisson E. C., Wojtulewski J. A. Measurement of side effects of drugs. Br Med J. 1974 Jun 29;2(5921):698–699. doi: 10.1136/bmj.2.5921.698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Letter: Naproxen (naprosyn) and gastrointestinal haemorrhage. Br Med J. 1974 Apr 6;2(5909):51–52. doi: 10.1136/bmj.2.5909.51-a. [DOI] [PMC free article] [PubMed] [Google Scholar]